West Pharmaceutical raises 2025 outlook as Q2 sales rise 9.2% to $766.5 million
West Pharmaceutical Services reported second-quarter 2025 net sales of $766.5 million, up 9.2%, with diluted EPS of $1.82 versus $1.51 a year earlier. The company raised its full-year 2025 net sales guidance to $3.040 billion to $3.060 billion and its adjusted-diluted EPS guidance to $6.65 to $6.85, both up from prior ranges.
Key points
- Q2 2025 net sales of $766.5 million rose 9.2%; organic net sales grew 6.8%.
- Adjusted-diluted EPS was $1.84, compared with $1.52 in the second quarter of 2024.
- Full-year 2025 adjusted-diluted EPS guidance rose to $6.65 to $6.85 from $6.15 to $6.35.
- Board approved a fourth-quarter 2025 dividend of $0.22 per share, payable November 19, 2025 to holders of record as of November 12, 2025.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.